ADAPTIN BIO, INC. (APTN): M&A transaction — Adaptin Bio files audited FY2024 financials; auditor warns of going concern doubt

ADAPTIN BIO, INC.

Net loss of $3.12M in 2024 vs $0.98M in 2023; no revenue reported.
Cash of only $34K as of Dec 31, 2024; accumulated deficit $4.12M.
Auditor expresses substantial doubt about ability to continue as going concern.
Convertible notes payable of $1.25M and derivative liability of $545K recorded.
Deferred equity issuance costs of $194K reflect planned capital raise; management cites need for additional funding.

item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ADAPTIN BIO, INC. underwent a change of control involving Unite Acquisition 1 Corp..

Action: change of control
Counterparty: Unite Acquisition 1 Corp.

Exact text from the filing

the completion of the Merger (as defined in the Original Report)

View on SEC.gov

Browse all m&a transactions →

ADAPTIN BIO, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-031875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.